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ABSTRACT
BACKGROUND Transmembrane prostate androgen-induced protein (TMEPAI) was 
reported to be highly amplified in the majority of patients with triple-negative breast 
cancer (TNBC). TMEPAI is related to poorer prognosis, limited treatment options, 
and prone to drug resistance compared with other proteins. One of the established 
markers to determine cancer resistance to drugs is the increased expression levels of 
drug efflux transporters. However, the role of TMEPAI in cancer resistance to drugs has 
not been elucidated. This study was aimed to investigate whether TMEPAI participates 
in cancer resistance to drugs by regulating drug efflux transporters.
METHODS TMEPAI knockout (KO) cells were previously developed from a TNBC cell 
line, Hs578T (wild-type/WT), using a CRISPR-Cas9 system. The expression levels of 
drug efflux transporters were determined in Hs578T-KO and Hs578-WT by quantitative 
reverse transcriptase polymerase chain reaction. Cytotoxic concentration 50% (CC50) 
of several anticancer drugs (doxorubicin, cisplatin, and paclitaxel) were determined 
in the two cell lines via 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium assay.
RESULTS The results showed that the mRNA expression of P-glycoprotein (P-gp) and 
breast cancer resistance protein (BCRP) was significantly increased in Hs578T-KO 
compared with that in Hs578T-WT cells. CC50 of several anticancer drugs investigated 
(doxorubicin, paclitaxel, and cisplatin) in Hs578T-KO cells was higher than that in 
Hs678-WT.
CONCLUSIONS TMEPAI participated in the regulation of mRNA expression levels in 
drug efflux transporters (P-gp, BCRP, and multidrug resistance-associated protein 1). 
Further studies are necessary to confirm whether this finding might be dependent on 
the development of cancer cell sensitivity to anticancer agents.
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Triple-negative breast cancer (TNBC) cells are 
characterized by the lack of the expression of 
estrogen receptor, progesterone receptor, and 
HER2/neu. TNBC has no targeted therapy yet.1 Even 
if it accounts for only 15–25% of total patients with 
breast cancer and 21% in 2011 in Indonesia, TNBC 
remains a major concern.2–4 It is responsible for 
more metastatic cases and breast cancer-related 
deaths in young women compared with other breast 
cancer subtypes.1 Moreover, treatment options using 
cytotoxic drugs for patients with TNBC are limited; 
patients eventually undergo resistance to anticancer 
agents, accounting for 90% treatment failure. One of 
the mechanisms in TNBC resistance to drugs is the 
overexpression of several drug-efflux transporters, 
such as multidrug resistance-associated protein 1 
(MRP1), P-glycoprotein (P-gp), and breast cancer 
resistance protein (BCRP).5
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Transmembrane prostate androgen-induced 
protein (TMEPAI) was first reported as a novel 
androgen-regulated gene.6 TMEPAI is also known 
as a prostate transmembrane protein, androgen 
induced 1, and solid tumor-associated gene 1.7 It 
is related to tumor relapse in the human prostate 
cancer xenograft model that is strongly androgen-
dependent.6 Instead of androgen, TMEPAI is induced 
by epidermal growth factor in breast and ovarian 
cancer cell lines and in breast primary tumors8 and 
transforming growth factor-β (TGF-β) in many cancer 
cell lines.9–11 In patients with TNBC, TMEPAI was 
reported to be highly amplified in 68.8% of patients 
and correlated with short survival time.2 Previous 
analysis of TMEPAI’s prognostic significance 
suggested that high TMEPAI expression is correlated 
with poor prognosis with a hazard ratio of 1.88 (p 
< 0.05).12 Previous study of Wardhani et al13 showed 
that TMEPAI also plays a role in cell proliferation. 
TMEPAI was also reported as a converter for TGF-β 
from a tumor suppressor in the early stages of 
carcinogenesis to a tumor promoter in advanced 
stages of carcinogenesis because of the inhibition 
of the TGF-β canonical Smad pathway and the 
enhancement of the TGF-β1-induced PI3K/AKT 
signaling pathway.5 Nevertheless, TMEPAI has been 
shown to contribute to TGF-β1-induced epithelial-
mesenchymal transition (EMT) in lung cancer 
cells, and it further induces drug resistance in 
pancreatic and lung cancer.14,15 However, to date, 
the role of TMEPAI in cancer resistance to drugs 
has not been elucidated. This study was aimed to 
investigate whether TMEPAI might participate 
in drug resistance by regulating drug efflux 
transporters.
METHODS
Cell culture 
This in vitro experimental study involved a 
TNBCcell line, Hs578T. The TNBC cell line Hs578T was 
obtained from Tsukuba University. Hs578T TMEPAI 
knockout (KO) cells were previously established 
from Hs578T wild-type (WT) using a CRISPR-Cas9 
system.16 Both WT and KO Hs578T were cultured in 
Dulbecco’s modified essential medium (Invitrogen) 
supplemented with 10% fetal bovine serum (Gibco), 10 
µg/ml insulin, 100 units/ml penicillin G, and 0.1 mg/ml 
streptomycin sulfate (Wako). Cells were maintained 
in a 5% CO
2
 incubator at 37°C. Cells were trypsinized 
at a confluency of about 80–90% and subjected to 
RNA isolation and quantitative reverse transcriptase 
polymerase chain reaction (qRT-PCR) analysis.
qRT-PCR
We isolated total RNA by using a Total RNA 
Mini Kit (Geneaid) from cultured cells, and RNA was 
converted to cDNA by using Transcriptor First Strand 
cDNA Synthesis Kit (Roche). RT-PCR was performed 
using FastStart Essential DNA Green (Roche). 
Primers used were purchased from Integrated DNA 
Technologies (IDT, Singapore) for β-actin, P-gp, 
MRP1, and BCRP. The sequences for P-gp were Fwd: 
5’-TTACATTCAGGTTTCATTTTGGTG-3’; P-gp Rev: 
5’-TCCTGTCGCATTATAGCATGA-3’; the sequences for 
BCRP were Fwd 5’-TTCGGCTTGCAACAACTATG-3’; 
BCRP Rev: 5’-TCCAGACACACCACGGATAA-3’; 
and the sequences for MRP1 were Fwd 
5’-ATGTCAACGTGGAATACCAGC-3’ and Rev: 5’- 
GAAGACTGAACTCCCTTCC-3’. β-actin was used as a 
housekeeping gene with the following sequences: 
β-actin Fwd: 5’-GCTGGAAGGTGGACAGCGA-3’, β-actin 
Rev: 5’-GGCATCGTGATGGACTCCG-3’.
Approximately 20 μl of the reaction was used 
in a 32-well plate on qRT-PCR Light Cycler Nano 
(Roche, USA). RT-PCR conditions comprised a three-
step amplification process (45 cycles) in a specific 
annealing temperature of 52°C for P-gp and BCRP but 
53°C for MRP1. The quantification cycle was analyzed 
by relative quantification using Livak method and 
described as normalized expression ratios of P-gp, 
BCRP, and MRP1 to β-actin.
Cytotoxic concentration
Cytotoxic concentration was measured based 
on cell viability via 3-(4,5-dimethylthiazol-2-yl)-
5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium (or MTS) assay by following the 
protocol in CellTiter 96® Aqueous One Solution Cell 
Proliferation Assay. About 1 × 104 cells were seeded 
in a 96-microplate, and cells were grown until about 
70% confluency. Subsequently, anticancer drugs 
were added 24 hours before performing MTS assay 
with cell confluence of at least 70%. Doxorubicin, 
paclitaxel, and cisplatin were dissolved in dimethyl 
sulfoxide (DMSO) and diluted until the required 
concentrations were obtained. DMSO used in final 
concentrations did not exceed 0.01%. DMSO was 
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used as control in this experiment. Concentrations 
used for doxorubicin, paclitaxel, and cisplatin were 
from 0.5–50 µM. CC50 of the three drugs was 
calculated from the extrapolation from log-linear 
equations.
Data analysis
The differences between the two groups, Hs578T 
WT and Hs578T KO, was analyzed using Student’s 
t-test. Significance was determined at p < 0.05.
RESULTS
Cell morphology 
The morphology of Hs578T WT and Hs578T KO cells 
is shown in Figure 1, a and b. No marked difference was 
observed in WT and KO cells.
  
Figure 1. Morphology in KO cells was not remarkably different 
from that in WT cells: (a) TNBC cell line, Hs578T, which has 
TMEPAI WT (Hs578T WT); (b) TNBC cell line, Hs578T, which 
has TMEPAI KO (Hs578T KO) by CRISPR-Cas9 systems. 
KO=knockout; WT=wild-type; TNBC=triple-negative breast 
cancer; TMEPAI=transmembrane prostate androgen-induced 
protein
TMEPAI modulates mRNA expression of drug efflux 
transporters in Hs578KO cells
Our results showed that TMEPAI affected the drug 
efflux transporters, especially P-gp and BCRP (Figure 
2). A slight increase in MRP1 was also found.
Figure 2. TMEPAI changed the mRNA expression level of drug-
efflux transporter: (a) P-gp mRNA expression level in Hs578T 
KO significantly increased compared with that in Hs578T-WT; 
(b) BCRP mRNA expression level in Hs578T KO significantly 
increased compared with that in Hs578T-WT; (c) MRP1 mRNA 
expression level increased in Hs578T-KO compared with 
that in Hs578T-WT. The mRNA expression was calculated as 
relative expression levels after normalization by β-actin as a 
housekeeping gene. All experiments were conducted in duplicate 
and repeated three times. Statistical analyses were performed 
using independent t-test. *p < 0.05. TMEPAI=transmembrane 
prostate androgen-induced protein; P-gp=P-glycoprotein; KO= 
knockout; WT=wild-type; BCRP=breast cancer resistance 
protein; MRP1=multidrug resistance-associated protein 1
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Figure 3. Decreased anticancer sensitivity in TMEPAI KO 
TNBC. Hs578T WT and KO were analyzed by MTS assay 
after 24 hours of anticancer treatment. All experiments 
were conducted in triplicate. Statistical analyses were 
performed using independent t-test. *p < 0.05. CC50= 
cytotoxic concentration 50; TMEPAI=transmembrane 
prostate androgen-induced protein; KO=knockout; TNBC= 
triple-negative breast cancer; WT=wild-type
Decreased sensitivity to anticancer drugs in Hs578T 
KO cells
In all the three most common anticancer drugs 
used in TNBC, a significant decrease in sensitivity to 
several anticancer drugs was noted (Figure 3). The 
increased sensitivity was most obvious in doxorubicin 
(2.8 times) and paclitaxel (2.3 times).
DISCUSSION
Given the high expression of TMEPAI in most 
patients with TNBC and its correlation with short 
survival and poor prognosis, we were interested 
to investigate it further. Regarding the molecular 
mechanism of TMEPAI, Watanabe et al11 and Singha et 
al2 reported that TMEPAI has tumorigenic activity in 
lung cancer and TNBC. The high expression of TMEPAI 
is also associated with oncogenic Snail expression.2 
Therefore, these reports suggested that TMEPAI may 
be correlated with tumorigenesis and drug resistance. 
However, the molecular mechanisms of TMEPAI in 
tumorigenesis and drug resistance remain unclear. This 
paper was focused on anticancer drugs resistance.
In a preclinical study, Lehmann et al17 identified 
that human TNBC subtypes display gene expression 
patterns. Hs578T was reported as a mesenchymal-
like subtype suggested for preclinical studies on the 
TGF-β pathway.17 This result was in accordance with 
TMEPAI research because of its involvement in the 
TGF-β pathway. We then considered morphological 
alterations in drug resistance. Chen et al18 reported 
morphological changes in doxorubicin-resistant cells 
compared with non-resistance cells using the BT20 cell 
line, an unclassified TNBC. They confirmed alterations 
in EMT markers, Snail and Twist, and morphological 
changes.18 In this model, no remarkable differences 
was observed in cell morphology between KO and 
WT (Figure 1, a and b). Singha et al2 reported that 
knockdown of TMEPAI TNBC cells demonstrates 
higher expression of Snail compared with WT. 
However, further experiments are necessary to 
determine whether the upregulation of EMT markers 
takes place in this models.
Currently, cytotoxic drugs are the backbone of 
TNBC treatments. Initially, the drugs show good 
efficacy, but cancer cells develop resistance to 
anticancer agents after a short period.5 Doxorubicin, 
paclitaxel, and cisplatin are commonly used in 
chemotherapy regimen. Doxorubicin kills cancer 
cells by intercalating into DNA and disrupting 
topoisomerase II-mediated DNA repair. Moreover, 
doxorubicin generates free radicals to harm cellular 
membranes.19 Paclitaxel is known to induce mitotic 
arrest, which leads to cell death.20 By contrast, 
cisplatin works by crosslinking with purine bases on 
DNA, interfering with the DNA repair mechanism, 
causing DNA damage, and promoting apoptosis in 
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cancer cells.21 These anticancer drugs, which are used 
in TNBC, address DNA damage and cell cycles.
The overexpression of drug efflux transporters 
such as P-gp, BCRP, and MRP1 is one of the most 
common mechanisms in drug resistance.22,23 
Doxorubicin, paclitaxel, and cisplatin are substrates 
for the three transporters, so increasing their 
expression will reduce the drug concentration in 
cancer cells.24 This finding is in accordance with this 
results. The increased expression of P-gp, BCRP, and 
MRP1 might lead to the efflux of anticancer agents 
from the cells. Hence, Hs578T KO demonstrated 
higher CC50 than WT cells.
This study investigated whether TMEPAI 
participates in drug resistance via the regulation of 
drug efflux transporters. This study results showed 
an enhancement in drug efflux transporters, followed 
by decreasing sensitivity of some anticancer agents. 
In line with this results, a previous study by Singha 
et al2 showed that TMEPAI inhibits TGF-β growth 
suppression and enhances PI3K/Akt signaling in TNBC.2 
In addition, Bhola et al25 reported that inhibition of the 
TGF-β pathways prevents drug resistance in cancer 
stem-like cells from TNBC. Li et al26 also showed that 
activating the PI3K/Akt pathways promotes multidrug 
resistance for doxorubicin, paclitaxel, and cisplatin 
in cervical cancer cell line with increasing drug efflux 
transporter. Thus, activation of PI3K/Akt might be the 
underlying pathway responsible for the contribution 
of TMEPAI in drug resistance. However further studies 
need to verify this proposed pathway.
This study showed that the transporters were 
modulated in the TMEPAI KO cell line (Hs578T KO). 
The results demonstrated significant alterations in 
the mRNA expression levels of P-gp and BCRP after 
TMEPAI knocked out in the TNBC cell line (Figure 2, a 
and b). In accordance with these results, Hs578T KO 
showed decreasing sensitivity to anticancer drugs 
(CC50 increased; Figure 3). The clinical relevance and 
various expression levels of TMEPAI in patients with 
TNBC and cell lines were proven by Singha et al.2 They 
suggested that TMEPAI is an appropriate biomarker 
in distinguishing the staged development of TNBC. To 
complete those results, data on anticancer sensitivity 
were provided. TMEPAI is suitable for biomolecular 
targets to increase the sensitivity of patients with 
TNBC to anticancer drugs. Further experiments are 
warranted to elucidate the molecular mechanism of 
TMEPAI in anticancer sensitivity.
In conclusion, this results suggested that TMEPAI 
played a key role in the regulation of drug efflux 
transporters, particularly P-gp and BCRP. However, 
further mechanism-based studies are necessary to 
confirm this findings.
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